A Phase 4 interventional study of Upadacitinib in Atopic Dermatitis, sponsored by AbbVie. Completed at 106 sites in 18 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-07-29.
Sponsored by AbbVie · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing upadacitinib in Dermatitis, Atopic — 2 open to participants now, 6 under way, 4 of them phase 3. upadacitinib · Dermatitis, Atopic.
Among the 17 studies testing upadacitinib in Dermatitis, Atopic, this one is the 8th largest by enrollment, is the only one that started in 2023, is one of 2 in phase 4, and was the 10th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →2 of the 17 studies testing upadacitinib in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+
RenJi Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 461 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 272 across the 17 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 17 have an industry lead sponsor. The 3 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
34 studies in Dermatitis, Atopic by AbbVie: 3 open now, 12 under way, 4 of them phase 3. Of 19 finished, 8 (42%) have results posted.
Among the 34 studies in Dermatitis, Atopic by AbbVie, this one is the 9th largest by enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2023, is the only one in phase 4, and was the 19th registered.
AbbVie’s Dermatitis, Atopic studies by the year they started, since 2016.
3 of the studies testing upadacitinib in Dermatitis, Atopic that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06389136Phase 3AbbVieA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | 2026-11 |
| NCT06701331Phase 3AbbVieSafety and Efficacy of Upadacitinib in Combination With Topical Corticosteroids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate to Severe Atopic Dermatitis | 2027-01 |
| NCT07678645RenJi HospitalThe Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching | 2027-11-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 17 studies testing upadacitinib in Dermatitis, Atopic, from their registry updates:
Among AbbVie’s 34 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study evaluates the dosing flexibility of upadacitinib in adult participants with moderate to severe AD. Adverse events and change in the disease activity will be assessed.
Upadacitinib is an approved drug for the treatment of moderate to severe/active immune-mediated inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis (UC), Crohn's Disease (CD), and AD. The study is comprised of a 35-day Screening Period, a 12-week double-blind period and a 12-week single-blind period. During the double-blind period, participants are placed in 1 of 2 groups, called treatment arms and will be randomized in a 1:1 ratio to receive upadacitinib. At 12 weeks during the single blind period, participants will be blinded to the upadacitinib dose based on their EASI response and reassigned to in 1 of 4 arms. After the last study visit, there is a 30-day follow-up visit. Approximately 454 adult participants ages 18 to 64 with moderate to severe AD who are candidates for systemic therapy will be enrolled at up to 160 sites worldwide.
The study is comprised of a 12-week double-blind period, followed by a 12-week single-blind period. Participants will receive upadacitinib oral tablets once daily for up to 24 weeks.
There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with current or past history of infection including:
Any of the following medical diseases or disorders:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 15 mg upadacitinib orally once daily (QD) for 12 weeks during the Double-Blind Treatment Period.
Drug: Upadacitinib
Participants received 30 mg upadacitinib orally once daily (QD) for 12 weeks during the Double-Blind Treatment Period.
Drug: Upadacitinib
At Week 12 in the Double-Blind Treatment Period, participants receiving 15 mg upadacitinib orally once daily (QD) achieving a ≥ 90% reduction in the Eczema Area and Severity Index (EASI) (≥ EASI 90) were allocated to receive 15 mg upadacitinib orally once daily (QD) for 12 weeks during the Single-Blind Treatment Period.
Drug: Upadacitinib
At Week 12 in the Double-Blind Treatment Period, participants receiving 15 mg upadacitinib orally once daily (QD) achieving a \< 90% reduction in the Eczema Area and Severity Index (EASI) (\< EASI 90) were allocated to receive 30 mg upadacitinib orally once daily (QD) for 12 weeks during the Single-Blind Treatment Period.
Drug: Upadacitinib
At Week 12 in the Double-Blind Treatment Period, participants receiving 30 mg upadacitinib orally once daily (QD) achieving a ≥ 90% reduction in the Eczema Area and Severity Index (EASI) (≥ EASI 90) were allocated to receive 15 mg upadacitinib orally once daily (QD) for 12 weeks during the Single-Blind Treatment Period.
Drug: Upadacitinib
At Week 12 in the Double-Blind Treatment Period, participants receiving 30 mg upadacitinib orally once daily (QD) achieving a \< 90% reduction in the Eczema Area and Severity Index (EASI) (\< EASI 90) were allocated to receive 30 mg upadacitinib orally once daily (QD) for 12 weeks during the Single-Blind Treatment Period.
Drug: Upadacitinib
Oral tablet
Also known as: RINVOQ, ABT-494
Percentage of Participants Achieving ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) at Week 24
The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%).
Time frame: Baseline and Week 24
Percentage of Participants Achieving ≥ 75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 75) at Week 24
The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%).
Time frame: Baseline and Week 24
Percentage of Participants Achieving a 100% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 100) at Week 24
The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%).
Time frame: Baseline and Week 24
Percentage of Participants Achieving ≥ 75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 75) at Week 12
The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%).
Time frame: Baseline and Week 12
Percentage of Participants Achieving ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) at Week 12
The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%).
Time frame: Baseline and Week 12
Percentage of Participants Achieving a 100% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 100) at Week 12
The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%).
Time frame: Baseline and Week 12
Percentage of Participants Achieving a ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) and Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at Week 12 Among Those With WP-NRS > 1 at Baseline
The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants rated itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
Time frame: Baseline and Week 12
Percentage of Participants Achieving a ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) and Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at Week 24 Among Those With WP-NRS > 1 at Baseline
The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants rated itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
Time frame: Baseline and Week 24
Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vlGA-AD) of 0 or 1 at Week 12
vIGA-AD is a validated assessment instrument used in clinical studies to rate the severity of AD globally. A 5-point scale is used to measure the severity of disease at the time of the investigator's evaluation of the participant ranging from 0 - Clear (no inflammatory signs of atopic dermatitis \[no erythema, no induration/papulation, no lichenification, no oozing/crusting\] Post-inflammatory hyperpigmentation and/or hypopigmentation may be present) to 4 - Severe (marked erythema \[deep or bright red\], marked induration/papulation, and/or marked lichenification).
Time frame: At Week 12
Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vlGA-AD) of 0 or 1 at Week 24
vIGA-AD is a validated assessment instrument used in clinical studies to rate the severity of AD globally. A 5-point scale is used to measure the severity of disease at the time of the investigator's evaluation of the participant ranging from 0 - Clear (no inflammatory signs of atopic dermatitis \[no erythema, no induration/papulation, no lichenification, no oozing/crusting\] Post-inflammatory hyperpigmentation and/or hypopigmentation may be present) to 4 - Severe (marked erythema \[deep or bright red\], marked induration/papulation, and/or marked lichenification).
Time frame: At Week 24
Percentage of Participants Achieving an Improvement (Reduction) in Worst Pruritus Numerical Rating Scale (WP-NRS) ≥4 at Week 12 Among Those With Baseline WP-NRS ≥4
The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants rated itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
Time frame: Baseline and Week 12
Percentage of Participants Achieving an Improvement (Reduction) in Worst Pruritus Numerical Rating Scale (WP-NRS) ≥4 at Week 24 Among Those With Baseline WP-NRS ≥4
The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants rated itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
Time frame: Baseline and Week 24
Percentage of Participants Achieving Worst Pruritus Numerical Rating Scale (WP-NRS) of 0 or 1 at Week 12 Among Those With Baseline WP-NRS >1
The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants rated itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
Time frame: Baseline and Week 12
Percentage of Participants Achieving Worst Pruritus Numerical Rating Scale (WP-NRS) of 0 or 1 at Week 24 Among Those With Baseline WP-NRS >1
The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants rated itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
Time frame: Baseline and Week 24
Percentage of Participants Achieving Improvement (Reduction) in Dermatology Life Quality Index (DLQI) ≥4 at Week 12 Among Those With Baseline DLQI ≥4
DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of atopic dermatitis (AD) disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of participant's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL.
Time frame: Baseline and Week 12
Percentage of Participants Achieving Improvement (Reduction) in Dermatology Life Quality Index (DLQI) ≥4 at Week 24 Among Those With Baseline DLQI ≥4
DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of atopic dermatitis (AD) disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of participant's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL.
Time frame: Baseline and Week 24
Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) of 0 or 1 At Week 12 Among Those With Baseline DLQI >1
DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of atopic dermatitis (AD) disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of participant's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL.
Time frame: Baseline and Week 12
Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) of 0 or 1 At Week 24 Among Those With Baseline DLQI >1
DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of atopic dermatitis (AD) disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of participant's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL.
Time frame: Baseline and Week 24
| Milestone | UPA 15 mg Double-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period | UPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period | UPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period |
|---|---|---|---|---|---|---|
| Started | 229 | 232 | 0 | 0 | 0 | 0 |
| Completed | 217 | 226 | 0 | 0 | 0 | 0 |
| Not completed | 12 | 6 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 7 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other, not specified | 5 | 4 | 0 | 0 | 0 | 0 |
| Milestone | UPA 15 mg Double-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period | UPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period | UPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 72 | 144 | 133 | 91 |
| Completed | 0 | 0 | 70 | 132 | 126 | 79 |
| Not completed | 0 | 0 | 2 | 12 | 7 | 12 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 2 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 5 | 2 | 6 |
| Withdrew: Other, not specified | 0 | 0 | 2 | 7 | 3 | 5 |
The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%).
| percentage of participants | UPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period | UPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period |
|---|---|---|---|---|
| Percentage of Participants Achieving ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) at Week 24 | 74.6 (64.5 to 84.8) | 48.1 (39.6 to 56.6) | 68.5 (60.5 to 76.4) | 29.3 (19.4 to 39.1) |
The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%).
| percentage of participants | UPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period | UPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period |
|---|---|---|---|---|
| Percentage of Participants Achieving ≥ 75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 75) at Week 24 | 97.2 (93.3 to 100.0) | 69.2 (61.3 to 77.0) | 88.5 (83.0 to 94.0) | 52.4 (41.6 to 63.2) |
The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%).
| percentage of participants | UPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period | UPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period |
|---|---|---|---|---|
| Percentage of Participants Achieving a 100% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 100) at Week 24 | 33.8 (22.8 to 44.8) | 7.5 (3.0 to 12.0) | 21.5 (14.5 to 28.6) | 3.7 (0.0 to 7.7) |
The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%).
| percentage of participants | UPA 15 mg Double-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period |
|---|---|---|
| Percentage of Participants Achieving ≥ 75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 75) at Week 12 | 64.4 (58.1 to 70.7) | 79.3 (74.0 to 84.6) |
The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%).
| percentage of participants | UPA 15 mg Double-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period |
|---|---|---|
| Percentage of Participants Achieving ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) at Week 12 | 33.8 (27.6 to 40.0) | 59.9 (53.5 to 66.3) |
The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%).
| percentage of participants | UPA 15 mg Double-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period |
|---|---|---|
| Percentage of Participants Achieving a 100% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 100) at Week 12 | 7.7 (4.2 to 11.2) | 15.9 (11.1 to 20.6) |
The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants rated itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
| percentage of participants | UPA 15 mg Double-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period |
|---|---|---|
| Percentage of Participants Achieving a ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) and Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at Week 12 Among Those With WP-NRS > 1 at Baseline | 18.0 (12.5 to 23.6) | 32.5 (25.9 to 39.1) |
The EASI is a composite index with scores ranging from 0 to 72. Four atopic dermatitis (AD) disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) assessed for severity on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants rated itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
| percentage of participants | UPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period | UPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period |
|---|---|---|---|---|
| Percentage of Participants Achieving a ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) and Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) at Week 24 Among Those With WP-NRS > 1 at Baseline | 38.5 (25.2 to 51.7) | 20.7 (12.0 to 29.5) | 35.0 (25.7 to 44.3) | 20.3 (10.1 to 30.6) |
vIGA-AD is a validated assessment instrument used in clinical studies to rate the severity of AD globally. A 5-point scale is used to measure the severity of disease at the time of the investigator's evaluation of the participant ranging from 0 - Clear (no inflammatory signs of atopic dermatitis \[no erythema, no induration/papulation, no lichenification, no oozing/crusting\] Post-inflammatory hyperpigmentation and/or hypopigmentation may be present) to 4 - Severe (marked erythema \[deep or bright red\], marked induration/papulation, and/or marked lichenification).
| percentage of participants | UPA 15 mg Double-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period |
|---|---|---|
| Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vlGA-AD) of 0 or 1 at Week 12 | 29.7 (23.7 to 35.7) | 51.5 (45.0 to 58.0) |
vIGA-AD is a validated assessment instrument used in clinical studies to rate the severity of AD globally. A 5-point scale is used to measure the severity of disease at the time of the investigator's evaluation of the participant ranging from 0 - Clear (no inflammatory signs of atopic dermatitis \[no erythema, no induration/papulation, no lichenification, no oozing/crusting\] Post-inflammatory hyperpigmentation and/or hypopigmentation may be present) to 4 - Severe (marked erythema \[deep or bright red\], marked induration/papulation, and/or marked lichenification).
| percentage of participants | UPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period | UPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period |
|---|---|---|---|---|
| Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vlGA-AD) of 0 or 1 at Week 24 | 63.4 (52.2 to 74.6) | 40.6 (32.3 to 48.9) | 52.3 (43.7 to 60.9) | 29.3 (19.4 to 39.1) |
The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants rated itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
| percentage of participants | UPA 15 mg Double-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period |
|---|---|---|
| Percentage of Participants Achieving an Improvement (Reduction) in Worst Pruritus Numerical Rating Scale (WP-NRS) ≥4 at Week 12 Among Those With Baseline WP-NRS ≥4 | 53.3 (46.0 to 60.5) | 67.7 (61.1 to 74.3) |
The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants rated itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
| percentage of participants | UPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period | UPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period |
|---|---|---|---|---|
| Percentage of Participants Achieving an Improvement (Reduction) in Worst Pruritus Numerical Rating Scale (WP-NRS) ≥4 at Week 24 Among Those With Baseline WP-NRS ≥4 | 73.1 (61.0 to 85.1) | 57.3 (46.6 to 68.0) | 67.0 (57.8 to 76.2) | 60.0 (47.6 to 72.4) |
The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants rated itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
| percentage of participants | UPA 15 mg Double-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period |
|---|---|---|
| Percentage of Participants Achieving Worst Pruritus Numerical Rating Scale (WP-NRS) of 0 or 1 at Week 12 Among Those With Baseline WP-NRS >1 | 27.3 (20.9 to 33.8) | 40.0 (33.1 to 46.9) |
The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants rated itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).
| percentage of participants | UPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period | UPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period |
|---|---|---|---|---|
| Percentage of Participants Achieving Worst Pruritus Numerical Rating Scale (WP-NRS) of 0 or 1 at Week 24 Among Those With Baseline WP-NRS >1 | 46.2 (32.6 to 59.7) | 32.5 (22.5 to 42.6) | 38.0 (28.5 to 47.5) | 28.3 (16.9 to 39.7) |
DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of atopic dermatitis (AD) disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of participant's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL.
| percentage of participants | UPA 15 mg Double-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period |
|---|---|---|
| Percentage of Participants Achieving Improvement (Reduction) in Dermatology Life Quality Index (DLQI) ≥4 at Week 12 Among Those With Baseline DLQI ≥4 | 77.5 (71.9 to 83.1) | 88.9 (84.7 to 93.1) |
DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of atopic dermatitis (AD) disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of participant's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL.
| percentage of participants | UPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period | UPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period |
|---|---|---|---|---|
| Percentage of Participants Achieving Improvement (Reduction) in Dermatology Life Quality Index (DLQI) ≥4 at Week 24 Among Those With Baseline DLQI ≥4 | 88.1 (80.3 to 95.8) | 82.2 (75.6 to 88.8) | 84.7 (78.3 to 91.0) | 74.0 (64.2 to 83.8) |
DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of atopic dermatitis (AD) disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of participant's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL.
| percentage of participants | UPA 15 mg Double-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period |
|---|---|---|
| Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) of 0 or 1 At Week 12 Among Those With Baseline DLQI >1 | 22.2 (16.7 to 27.8) | 36.5 (30.2 to 42.8) |
DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of atopic dermatitis (AD) disease symptoms and treatment on health-related quality of life (HRQoL). It consists of 10 questions assessing impact of skin diseases on different aspects of participant's QoL over the prior week. Each item is scored on a 4-point scale: 0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much. Item scores (0 to 3) are added to provide a total score range of 0 to 30. Higher scores indicate greater impairment of HRQoL.
| percentage of participants | UPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period | UPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period |
|---|---|---|---|---|
| Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) of 0 or 1 At Week 24 Among Those With Baseline DLQI >1 | 42.0 (30.4 to 53.7) | 24.0 (16.7 to 31.4) | 35.4 (27.1 to 43.8) | 15.2 (7.3 to 23.1) |
Collected over All-cause mortality and adverse event tables include events reported from the time informed consent was signed to the end of the study. The median time on follow-up was 168 days for the Double-Blind Treatment Period groups and ranged from 168 to 169 days for the Single-Blind Treatment Period groups.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| UPA 15 mg Double-Blind Treatment Period | 0/229 (0%) | 8/229 (3.5%) | 41/229 (17.9%) |
| UPA 30 mg Double-Blind Treatment Period | 0/232 (0%) | 0/232 (0%) | 67/232 (28.9%) |
| UPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period | 0/72 (0%) | 1/72 (1.4%) | 17/72 (23.6%) |
| UPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period | 0/144 (0%) | 1/144 (0.7%) | 38/144 (26.4%) |
| UPA 30 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period | 0/133 (0%) | 1/133 (0.8%) | 39/133 (29.3%) |
| UPA 30 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period | 0/91 (0%) | 0/91 (0%) | 33/91 (36.3%) |
| Event | UPA 15 mg Double-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period | UPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period | UPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period |
|---|---|---|---|---|---|---|
| ACUTE MYOCARDIAL INFARCTIONCardiac disorders | 0/229 | 0/232 | 1/72 | 0/144 | 0/133 | 0/91 |
| HUMERUS FRACTUREInjury, poisoning and procedural complications | 0/229 | 0/232 | 0/72 | 0/144 | 1/133 | 0/91 |
| PYELONEPHRITISInfections and infestations | 0/229 | 0/232 | 0/72 | 1/144 | 0/133 | 0/91 |
| CORONARY ARTERY DISEASECardiac disorders | 1/229 | 0/232 | 0/72 | 0/144 | 0/133 | 0/91 |
| TOXIC NODULAR GOITREEndocrine disorders | 1/229 | 0/232 | 0/72 | 0/144 | 0/133 | 0/91 |
| EPIDIDYMITISInfections and infestations | 1/229 | 0/232 | 0/72 | 0/144 | 0/133 | 0/91 |
| ERYSIPELASInfections and infestations | 1/229 | 0/232 | 0/72 | 0/144 | 0/133 | 0/91 |
| FALLInjury, poisoning and procedural complications | 1/229 | 0/232 | 0/72 | 0/144 | 0/133 | 0/91 |
| HAND FRACTUREInjury, poisoning and procedural complications | 1/229 | 0/232 | 0/72 | 0/144 | 0/133 | 0/91 |
| SPINAL COMPRESSION FRACTUREInjury, poisoning and procedural complications | 1/229 | 0/232 | 0/72 | 0/144 | 0/133 | 0/91 |
| Event | UPA 15 mg Double-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period | UPA 15 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period | UPA 15 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period --> UPA 15 mg Single-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period --> UPA 30 mg Single-Blind Treatment Period |
|---|---|---|---|---|---|---|
| DERMATITIS ATOPICSkin and subcutaneous tissue disorders | 7/229 | 9/232 | 6/72 | 23/144 | 16/133 | 15/91 |
| ACNESkin and subcutaneous tissue disorders | 16/229 | 32/232 | 1/72 | 4/144 | 8/133 | 6/91 |
| NASOPHARYNGITISInfections and infestations | 13/229 | 21/232 | 8/72 | 6/144 | 10/133 | 2/91 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 8/229 | 9/232 | 5/72 | 3/144 | 4/133 | 4/91 |
| ORAL HERPESInfections and infestations | 4/229 | 2/232 | 0/72 | 0/144 | 3/133 | 5/91 |
| ECZEMASkin and subcutaneous tissue disorders | 3/229 | 2/232 | 0/72 | 2/144 | 1/133 | 5/91 |
ITT\_1 Population: all participants who were randomized in the Double-Blind Treatment Period
| Age, Continuous(years) | UPA 15 mg Double-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period | Total |
|---|---|---|---|
| Mean | 34.4 ± 12.06 | 32.7 ± 10.83 | 33.5 ± 11.48 |
| Sex: Female, Male(Participants) | UPA 15 mg Double-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period | Total |
|---|---|---|---|
| Female | 95 | 110 | 205 |
| Male | 134 | 122 | 256 |
| Ethnicity (NIH/OMB)(Participants) | UPA 15 mg Double-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period | Total |
|---|---|---|---|
| Hispanic or Latino | 10 | 9 | 19 |
| Not Hispanic or Latino | 219 | 223 | 442 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | UPA 15 mg Double-Blind Treatment Period | UPA 30 mg Double-Blind Treatment Period | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 67 | 66 | 133 |
| Native Hawaiian or Other Pacific Islander | 2 | 4 | 6 |
| Black or African American | 2 | 3 | 5 |
| White | 155 | 158 | 313 |
| More than one race | 2 | 0 | 2 |
| Unknown or Not Reported | 0 | 1 | 1 |
Showing the first 100 of 106 sites across 18 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
Ran from May 2023 to primary completion in Jul 2024, 13 months.
Results were first posted in Jul 2025, 1 year after primary completion.
Of 45 phase 4 interventional studies under Dermatitis, Atopic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 13 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Upadacitinib